Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

In conclusion, COPD is a global disease, with increasing prevalence and health-related impact. The loss of FEV 1 may be slowing down, but what is really needed is an intervention that improves it in ...

Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate or ...

Among older adults with established ASCVD, hospitalization for COPD increases risk of ASCVD hospitalization. The risk for atherosclerotic cardiovascular disease (ASCVD) hospitalization after chronic ...